STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNDA
  4. [Form 3] Vanda Pharmaceuticals Inc. Initial Statement of Beneficial Ownership

Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Vanda Pharmaceuticals executive Daniel Patrick McGuire, SVP, GC and Secretary, filed an initial Form 3 reporting his beneficial ownership of common stock and restricted stock units. The holdings include several RSU awards that vest in equal annual installments between July 29, 2026 and March 1, 2029, contingent on continued employment.

Positive

  • None.

Negative

  • None.
Insider McGuire Daniel Patrick
Role SVP, GC and Secretary
Type Security Shares Price Value
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,732 shares (Direct, null)
Footnotes (1)
  1. Represents shares of common stock underlying an RSU award. One-third of the RSU will vest on July 29, 2026, 1/3 will vest on July 29, 2027, and the remaining 1/3 will vest on July 29, 2028, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest. Represents shares of common stock underlying an RSU award. The RSU vests as follows: 1/3 will vest on March 1, 2027, 1/3 will vest on March 1, 2028, and the remaining 1/3 will vest on March 1, 2029, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest. Represents shares of common stock underlying an RSU award. The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
Common stock holding 20,000 shares Total shares following holding entry as of June 4, 2026
Common stock holding 6,000 shares Total shares following holding entry as of June 4, 2026
Common stock holding 2,250 shares Total shares following holding entry as of June 4, 2026
Common stock holding 1,732 shares Total shares following holding entry as of June 4, 2026
RSU vesting dates July 29, 2026/2027/2028 One-third of an RSU award vests on each date
RSU vesting dates March 1, 2027/2028/2029 One-third of another RSU award vests on each date
Four-year RSU schedule First vest March 1, 2027 RSU vests in four equal annual installments starting this date
RSU award financial
"Represents shares of common stock underlying an RSU award."
First Permissible Trading Day financial
"Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest."
vesting financial
"One-third of the RSU will vest on July 29, 2026, 1/3 will vest on July 29, 2027, and the remaining 1/3 will vest on July 29, 2028"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3 regulatory
"filed an initial Form 3 reporting his beneficial ownership of common stock and restricted stock units"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
McGuire Daniel Patrick
(Last)(First)(Middle)
2200 PENNSYLVANIA AVE. NW
SUITE 300E
(Street)
WASHINGTON DISTRICT OF COLUMBIA 20037
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2026		3. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, GC and Secretary
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock1,732D
Common Stock6,000(1)D
Common Stock2,250(2)D
Common Stock20,000(3)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock underlying an RSU award. One-third of the RSU will vest on July 29, 2026, 1/3 will vest on July 29, 2027, and the remaining 1/3 will vest on July 29, 2028, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
2. Represents shares of common stock underlying an RSU award. The RSU vests as follows: 1/3 will vest on March 1, 2027, 1/3 will vest on March 1, 2028, and the remaining 1/3 will vest on March 1, 2029, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
3. Represents shares of common stock underlying an RSU award. The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
/s/ Daniel McGuire06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Daniel Patrick McGuire’s Form 3 show for Vanda Pharmaceuticals (VNDA)?

The Form 3 shows Daniel Patrick McGuire, SVP, GC and Secretary of Vanda Pharmaceuticals, reporting direct beneficial ownership of common stock and several restricted stock unit (RSU) awards, establishing his initial equity position as an insider of the company.

Does the Vanda (VNDA) Form 3 for Daniel McGuire report any stock purchases or sales?

The filing does not report any explicit stock purchases or sales. It primarily lists Daniel McGuire’s existing holdings in Vanda common stock and RSU awards, with all transaction directions coded as unknown and summarized as neutral in the transaction data.

What RSU vesting schedule is disclosed for Daniel McGuire’s Vanda (VNDA) awards?

One RSU award vests one-third on July 29, 2026, 2027, and 2028. Another vests one-third on March 1, 2027, 2028, and 2029. A third vests in four equal annual installments starting March 1, 2027, assuming continuous employment.

How will vested RSU shares be delivered in Daniel McGuire’s Vanda (VNDA) Form 3?

For each RSU award, vested shares will be delivered on the first permissible trading day occurring on or after the applicable vesting date, as long as Daniel McGuire remains continuously employed through each vesting milestone.

What are Daniel McGuire’s direct common stock holdings reported in the Vanda (VNDA) Form 3?

The Form 3 lists multiple direct common stock-related holdings, with position sizes including 20,000 shares, 6,000 shares, 2,250 shares, and 1,732 shares. Several of these represent common stock underlying RSU awards subject to future vesting conditions.